Detection of EGFR mutation and its association with clinicopathological features of non-small cell lung cancer patients
##plugins.themes.academic_pro.article.main##
Author
-
Tran Huu ThienThe University of Danang - VN-UK Institute for Research and Executive EducationNguyen An Thi VietThe University of Danang - VN-UK Institute for Research and Executive EducationDoan Minh ThuThe University of Danang - VN-UK Institute for Research and Executive EducationNguyen Ngoc QuangPathology and Molecular Biology Center, National Cancer Hospital K, HanoiVuong Dieu LinhPathology and Molecular Biology Center, National Cancer Hospital K, Hanoi
Từ khóa:
Tóm tắt
Alterations in the epidermal growth factor receptor were confirmed to take a significant role in targeted therapy for patients with lung cancer. Studied 299 non-small cell lung cancer patients to determine the distribution of EGFR mutation and its relationship with clinicopathological characteristics of patients. EGFR mutations were analysed by allele-specific PCR on the Cobas z480 system, and the association between EGFR mutations and patient characteristics was analysed by Pearson Chi-square test and Fisher extract test. The results showed that the frequency of EGFR mutation was 38.8%, in which, Ex19Del and L858R substitution were predominant among overall mutation, 45.4% and 29.1%, respectively. There was no difference between EGFR mutations with age, specimen type, tumour size and histopathological subtype. However, there was a strong correlation between EGFR mutation and gender and tumour status (p<0.05). In particularly, Ex19Del and L858R mutation were positively associated with females, while the G719X substitution mainly occurred in male patients.
Tài liệu tham khảo
-
[1] Sung, Hyuna et al. "Global Cancer Statistics 2020: GLOBOCAN Estimates Of Incidence And Mortality Worldwide For 36 Cancers In 185 Countries". CA: A Cancer Journal For Clinicians, vol 71, no. 3, 2021, pp. 209-249. Wiley, https://doi.org/10.3322/caac.21660.
[2] Blandin Knight, Sean et al. "Progress And Prospects Of Early Detection In Lung Cancer". Open Biology, vol 7, no. 9, 2017, p. 170070. The Royal Society, https://doi.org/10.1098/rsob.170070.
[3] Chan, S.K. et al. "Mutations Of The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer – Search And Destroy". European Journal Of Cancer, vol 42, no. 1, 2006, pp. 17-23. Elsevier BV, https://doi.org/10.1016/j.ejca.2005.07.031.
[4] "NCCN Clinical Practice Guidelines In Non-Small Cell Lung Cancer V3.2022". NCCN, 2022, https://www.nccn.org/professionals/phy-sician_gls/pdf/nscl.pdf. Accessed 25 June 2022
[5] Bethune, Gillian et al. "Epidermal Growth Factor Receptor (EGFR) In Lung Cancer: An Overview And Update". Pubmed Central (PMC), 2022, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256436/. Accessed 25 June 2022
[6] Yoneda, Kazue et al. "Treatment Of Non-Small Cell Lung Cancer With EGFR Mutations". Journal Of UOEH, vol 41, no. 2, 2019, pp. 153-163. The University Of Occupational And Environmental Health, Japan, https://doi.org/10.7888/ju-oeh.41.153. Accessed 25 June 2022.
[7] Melosky, Barbara et al. "Worldwide Prevalence Of Epidermal Growth Factor Receptor Mutations In Non-Small Cell Lung Cancer: A Meta-Analysis". Molecular Diagnosis & Therapy, vol 26, no. 1, 2021, pp. 7-18. Springer Science And Business Media LLC, https://doi.org/10.1007/s40291-021-00563-1. Accessed 25 June 2022.
[8] Zhou, Wei, and David C. Christiani. "East Meets West: Ethnic Differences In Epidemiology And Clinical Behaviors Of Lung Cancer Between East Asians And Caucasians". Chinese Journal Of Cancer, vol 30, no. 5, 2011, pp. 287-292. Editorial Office Of Chinese Journal Of Cancer, https://doi.org/10.5732/cjc.011.10106. Accessed 25 June 2022.
[9] Mao, Linlin et al. "Mutation Spectrum Of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested By Multiple Methods In A CAP-Accredited Laboratory". Pathology And Oncology Research, vol 27, 2021. Frontiers Media SA, https://doi.org/10.3389/pore.2021.602726. Accessed 25 June 2022.
[10] Dang, Anh-Thu Huynh et al. "Actionable Mutation Profiles Of Non-Small Cell Lung Cancer Patients From Vietnamese Population". Scientific Reports, vol 10, no. 1, 2020. Springer Science And Business Media LLC, https://doi.org/10.1038/s41598-020-59744-3. Accessed 25 June 2022.
[11] Vu, Thanh et al. "Effectiveness And Tolerability Of First-Line Afatinib For Advanced EGFR-Mutant Non-Small Cell Lung Cancer In Vietnam". Asian Pacific Journal of Cancer Prevention, vol 22, no. 5, 2021, pp. 1581-1590. Epismart Science Vector Ltd, https://doi.org/10.31557/apjcp.2021.22.5.1581. Accessed 25 June 2022.
[12] Benbrahim, Zineb et al. "EGFR Mutation Frequency In Middle East And African Non-Small Cell Lung Cancer Patients: A Systematic Review And Meta-Analysis". BMC Cancer, vol 18, no. 1, 2018. Springer Science And Business Media LLC, https://doi.org/10.1186/s12885-018-4774-y. Accessed 25 June 2022.
[13] Gahr, S et al. "EGFR Mutational Status In A Large Series Of Caucasian European NSCLC Patients: Data From Daily Practice". British Journal Of Cancer, vol 109, no. 7, 2013, pp. 1821-1828. Springer Science And Business Media LLC, https://doi.org/10.1038/bjc.2013.511. Accessed 25 June 2022.
[14] Castellanos, Emily et al. "Driven By Mutations: The Predictive Value Of Mutation Subtype In EGFR -Mutated Non–Small Cell Lung Cancer". Journal Of Thoracic Oncology, vol 12, no. 4, 2017, pp. 612-623. Elsevier BV, https://doi.org/10.1016/jtho.2016.12.014. Accessed 25 June 2022.
[15] Zhou, Xiuzhi et al. "Analyzing EGFR Mutations And Their Association With Clinicopathological Characteristics And Prognosis Of Patients With Lung Adenocarcinoma". Oncology Letters, 2018. Spandidos Publications, https://doi.org/10.3892/2018.8681. Accessed 25 June 2022.
[16] O’Kane, Grainne M. et al. "Uncommon EGFR Mutations In Advanced Non-Small Cell Lung Cancer". Lung Cancer, vol 109, 2017, pp. 137-144. Elsevier BV, https://doi.org/10.1016/lungcan.2017.04.016. Accessed 1 July 2022. Accessed 25 June 2022.
[17] Chen, Li-Yang et al. "Coexistence Of EGFR T790M Mutation And Common Activating Mutations In Pretreatment Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis". Lung Cancer, vol 94, 2016, pp. 46-53. Elsevier BV, https://doi.org/10.1016/j.lung-can.2016.01.019. Accessed 25 June 2022.
[18] Liang, Hengrui et al. "The Alteration Of T790M Between 19 Del And L858R In NSCLC In The Course Of EGFR-Tkis Therapy: A Literature-Based Pooled Analysis". Journal Of Thoracic Disease, vol 10, no. 4, 2018, pp. 2311-2320. AME Publishing Company, https://doi.org/10.21037/jtd.2018.03.150. Accessed 25 June 2022.
[19] Jin, Ying et al. "Distinct Co-Acquired Alterations And Genomic Evolution During TKI Treatment In Non-Small-Cell Lung Cancer Patients With Or Without Acquired T790M Mutation". Oncogene, vol 39, no. 9, 2019, pp. 1846-1859. Springer Science And Business Media LLC, https://doi.org/10.1038/s41388-019-1104-z. Accessed 25 June 2022.
[20] Pao, William et al. "Acquired Resistance Of Lung Adenocarcinomas To Gefitinib Or Erlotinib Is Associated With A Second Mutation In The EGFR Kinase Domain". Plos Medicine, vol 2, no. 3, 2005, p. e73. Public Library Of Science (Plos), https://doi.org/10.1371/jour-nal.pmed.0020073. Accessed 25 June 2022.
[21] Shi, Yuankai et al. "A Prospective, Molecular Epidemiology Study Of EGFR Mutations In Asian Patients With Advanced Non–Small-Cell Lung Cancer Of Adenocarcinoma Histology (PIONEER)". Journal Of Thoracic Oncology, vol 9, no. 2, 2014, pp. 154-162. Elsevier BV, https://doi.org/10.1097/jto.0000000000000033. Accessed 25 June 2022.
[22] Cai, Yangyang et al. "Successful Treatment Of A Patient With NSCLC Carrying Uncommon Compound EGFR G719X And S768I Mutations Using Osimertinib: A Case Report". Journal Of International Medical Research, vol 48, no. 6, 2020, p. 030006052092879. SAGE Publications, https://doi.org/10.1177/0300060520928793. Accessed 25 June 2022.
[23] Suda, Kenichi et al. "Clinical Impacts Of EGFR Mutation Status: Analysis Of 5780 Surgically Resected Lung Cancer Cases". The Annals Of Thoracic Surgery, vol 111, no. 1, 2021, pp. 269-276. Elsevier BV, https://doi.org/10.1016/j.athoracsur.2020.05.041. Accessed 25 June 2022.
[24] Gaur, Priyanka et al. "EGFR Mutation Detection And Its Association With Clinicopathological Characters Of Lung Cancer Patients". World Journal Of Oncology, vol 9, no. 5-6, 2018, pp. 151-155. Elmer Press, Inc., https://doi.org/10.14740/wjon1167. Accessed 25 June 2022.
[25] Hu, Zhihuang et al. "Hormone Receptor Expression Correlates With EGFR Gene Mutation In Lung Cancer In Patients With Simultaneous Primary Breast Cancer". Translational Lung Cancer Research, vol 9, no. 2, 2020, pp. 325-336. AME Publishing Company, https://doi.org/10.21037/tlcr-20-513. Accessed 26 June 2022.
[26] Cho, Jaeyoung et al. "The Association Of EGFR Mutations With Stage At Diagnosis In Lung Adenocarcinomas". PLOS ONE, vol 11, no. 11, 2016, p. e0166821. Public Library Of Science (Plos), https://doi.org/10.1371/journal.pone.0166821. Accessed 26 June 2022.
[27] Sholl, Lynette M. et al. "Multi-Institutional Oncogenic Driver Mutation Analysis In Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience". Journal Of Thoracic Oncology, vol 10, no. 5, 2015, pp. 768-777. Elsevier BV, https://doi.org/10.1097/0000000000000516. Accessed 26 June 2022.
[28] Liang, Hengrui et al. "Concomitant Mutations In EGFR 19Del/L858R Mutation And Their Association With Response To EGFR-Tkis In NSCLC Patients;". Cancer Management And Research, vol 12, 2020, pp. 8653-8662. Informa UK Limited, https://doi.org/10.2147/cmar.s255967. Accessed 26 June 2022.
[29] Hong, Weiwei et al. "Prognostic Value Of EGFR 19‑Del And 21‑L858R Mutations In Patients With Non-Small Cell Lung Cancer". Oncology Letters, 2019. Spandidos Publications, https://doi.org/10.3892/ol.2019.10715. Accessed 30 June 2022.
[30] Li, Kaidi et al. "Determining EGFR-TKI Sensitivity Of G719X And Other Uncommon EGFR Mutations In Non-Small Cell Lung Cancer: Perplexity And Solution". Oncology Reports, vol 37, no. 3, 2017, pp. 1347-1358. Spandidos Publications, https://doi.org/10.3892/or.2017.5409. It was accessed on 26 June 2022.